---
schema_version: "secwatch.filing_event.v1"
accession: "0001779128-23-000075"
form_type: "8-K"
ticker: "SRTA"
cik: "0001779128"
company_name: "Strata Critical Medical, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:57:57.953828+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Blade Q2 revenue $61M (+71%), medical $34.4M (+99%), net loss $12.2M

## Summary
- Q2 revenue $61.0M (+71% YoY); medical revenue $34.4M (+99% YoY, +29% sequentially).
- Flight Profit $10.4M (+103% YoY); Flight Margin 17.0% vs 14.3%.
- GAAP net loss $12.2M vs net income $8.4M in prior-year quarter.
- Adjusted EBITDA -$4.4M vs -$6.1M, improved 27%; Medical Adj. EBITDA $3.0M.
- Short Distance revenue up 75% YoY, driven by Blade Europe acquisition and organic growth.

## SEC filing metadata
- accession: 0001779128-23-000075
- form_type: 8-K
- ticker: SRTA
- cik: 0001779128
- company_name: Strata Critical Medical, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1779128/000177912823000075/0001779128-23-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1779128/000177912823000075/blde-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001779128-23-000075
- JSON: https://secwatch.observer/filing/0001779128-23-000075.json
- Plain text: https://secwatch.observer/filing/0001779128-23-000075.txt

## Key facts
- Earnings Releases
  Strata Critical Medical, Inc. reported second quarter ended June 30, 2023 results: revenue $61.0 million, net income $(12,232).
  - Period: second quarter ended June 30, 2023
  - Revenue: $61.0 million
  - Net income: $(12,232)
  - Result: reported results
  source text: 9, 2023 Blade Air Mobility Reports Financial Results for the Second Quarter Ended June 30, 2023 • Second quarter ended June 30, 2023 revenue up 71% versus the prior year to $61.0 million • Medical revenue of $34.4 million in Q2 2023 up 99% versus the prior year period, up 29% sequentially versus Q1 2023 • Short Distance revenue up 75% in Q2 2023 versus the prior
  evidence_url: https://www.sec.gov/Archives/edgar/data/1779128/000177912823000075/0001779128-23-000075-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.